Highlights for the Quarter
  • Continuation of talent recruitment campaign with additional hires in engineering, quality assurance and finance.
  • New strategic distribution partnership with China-based Sinsi Technology Co Ltd to expand global reach.
  • Finalising preparation for submission to FDA for 510(k) approval to market InVivage® clinical device for use in human oral cancer screening.
  • Total Cash Flows of ($1.4m) for the Quarter with Cash Flows from Operating Activities of ($1.3m) for the Quarter ending 30 June 2022.

Full Report: Optiscan Quarterly Announcement (30 June 2022)

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Optiscan Imaging Limited published this content on 22 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 August 2022 02:55:03 UTC.